Development of Commercial Manufacturing Processes for Acalabrutinib-Reference-Cited by-同舟云学术

Development of Commercial Manufacturing Processes for Acalabrutinib

Published:2022-12-06 Issue:12 Volume:26 Page:3303-3311
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Bethel Paul A.¹,Chan Lai Chun¹,Cooper Katie¹,Ensor Gareth J.¹,Evarts Jerry²,Garrey Rustam³,Ford J. Gair¹^ORCID,Harding Daniel¹,Hughes Shaun¹,Jackson Lucy¹,Golden Michael¹^ORCID,Millard Kirsty¹,Phillips Andrew¹,Robbins Andrew¹,Short David³,Telford Alex¹,Whittaker David T. E.⁴

Affiliation:

1. Pharmaceutical Technology and Development, AstraZeneca, Macclesfield SK10 2NA, U.K.

2. Acerta Pharma, 121 Oyster Point Blvd., South San Francisco, California 94080, United States

3. W.R. Grace & Co., 1290 Industrial Way, Albany, Oregon 97322, United States

4. Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.2c00304

Reference8 articles.

1. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

2. Tjeerd, B.; Jans, C.; Man, P.; Oubrie, A.; Raaijmakers, H.; Rewinkel, J.; Sterrenburg, J.G.; Wijkmans, J. 4-Imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BTK inhibitors. U.S. Patent 9,290,504 B2, 2013.

3. Thermal Stability of 2-Butynoic Acid (Tetrolic Acid)

4. A Manufacturing Process to an Intermediate in the Synthesis of Acalabrutinib

5. International Conference on Harmonisation (ICH) Q11 (Development and Manufacture of Drug Substances), 2012.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. (o-CF₃PhO)₃P as a simple coupling reagent for direct amidation via activation of amines;Organic Chemistry Frontiers;2024